David Baker - Neoleukin Therapeutics Cofounder Board
Insider
David Baker is Cofounder Board of Neoleukin Therapeutics
| Phone | 855 226 6447 |
| Web | https://www.neoleukin.com |
David Baker Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Baker against Neoleukin Therapeutics stock is an integral part of due diligence when investing in Neoleukin Therapeutics. David Baker insider activity provides valuable insight into whether Neoleukin Therapeutics is net buyers or sellers over its current business cycle. Note, Neoleukin Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Neoleukin Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Baker over a month ago Disposition of 246 shares by David Baker of Aspen Technology at 248.95 subject to Rule 16b-3 | ||
David Baker over three months ago Acquisition by David Baker of 2400 shares of Bassett Furniture at 17.55 subject to Rule 16b-3 | ||
David Baker over three months ago Disposition of 832 shares by David Baker of Aspen Technology at 234.14 subject to Rule 16b-3 | ||
David Baker over six months ago Acquisition by David Baker of 4002 shares of Aspen Technology subject to Rule 16b-3 |
Neoleukin Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1871) % which means that it has lost $0.1871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3788) %, meaning that it created substantial loss on money invested by shareholders. Neoleukin Therapeutics' management efficiency ratios could be used to measure how well Neoleukin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Neoleukin Therapeutics currently holds 12.07 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Neoleukin Therapeutics has a current ratio of 12.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neoleukin Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MD FACP | NextCure | 71 | |
| W Vernon | Nuvation Bio | 65 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| David Hanley | Nuvation Bio | 55 | |
| Timothy Moore | Instil Bio | 63 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| Bronson Crouch | Instil Bio | 52 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Stacy Markel | Nuvation Bio | 60 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Satyavrat CFA | Spero Therapeutics | 52 | |
| Kerry Wentworth | Nuvation Bio | 52 | |
| Gary Hattersley | Nuvation Bio | 58 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Michael MSBA | NextCure | 64 | |
| Christopher Ogden | CytomX Therapeutics | 41 | |
| Uri MD | Assembly Biosciences | 53 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Hoyoung MD | CytomX Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 |
Neoleukin Therapeutics Leadership Team
Elected by the shareholders, the Neoleukin Therapeutics' board of directors comprises two types of representatives: Neoleukin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neoleukin. The board's role is to monitor Neoleukin Therapeutics' management team and ensure that shareholders' interests are well served. Neoleukin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neoleukin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Umut Ulge, VP Devel | ||
| MS MD, Chief Officer | ||
| Donna JD, Gen Legal | ||
| Carl Walkey, Sr Devel | ||
| Bill Arthur, VP Research | ||
| Sean Smith, VP Officer | ||
| Kamran Alam, CFO, Vice President - Finance | ||
| David Baker, Cofounder Board | ||
| Jonathan MD, President, CEO |
Neoleukin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neoleukin Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |